Publications by authors named "Matteo Pasca"

Claim this Profile
M
Multi-Criterial Model for Weighting Biological Risk Factors in Multiple Sclerosis: Clinical and Health Insurance Implications.
Roberto De Masi, Stefania Orlando, Chiara Leo, Matteo Pasca, Luca Anzilli

Healthcare (Basel)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis.
Alice Mariottini, Leonardo Marchi, Chiara Innocenti, Maria Di Cristinzi, Matteo Pasca

Front Neurol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis.
Matteo Pasca, Benedetta Forci, Alice Mariottini, Claudia Mechi, Alessandro Barilaro

Mult Scler Relat Disord· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of recurrent progressive multifocal leukoencephalopathy after human stem cell transplant, with detection of John Cunningham virus and human herpesvirus 6 on cerebrospinal fluid, treated with Mirtazapine, Olanzapine and Foscarnet.
Matteo Pasca, Antonella Picchioni, Salvatore Mazzeo, Federica Terenzi, Elio Prestipino

Intractable Rare Dis Res· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute Symptomatic Sinus Bradycardia in High-Dose Methylprednisolone Therapy in a Woman With Inflammatory Myelitis: A Case Report and Review of the Literature.
Alessandro Sodero, Martina Squitieri, Salvatore Mazzeo, Matteo Pasca, Sabrina Matà

Clin Med Insights Case Rep· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Luca Prosperini, Pietro Annovazzi, Laura Boffa, Maria Chiara Buscarinu, Antonio Gallo, Matteo Pasca

J Neurol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis